<tt id="msi8q"></tt>
  • <nav id="msi8q"><strong id="msi8q"></strong></nav><menu id="msi8q"><menu id="msi8q"></menu></menu>
  • <menu id="msi8q"><menu id="msi8q"></menu></menu>
    <nav id="msi8q"><code id="msi8q"></code></nav><menu id="msi8q"></menu>
    ?

    SIFT
    Search Results:31 Num
    2022/ 08/ 11
    Maxinovel announces dosing of first patient in Phase I/II study of MAX-40279 combined with KN046 in advanced solid tumor

    Maxinovel announces dosing of first patient in Phase I/II study of MAX-40279 combined with KN046 in advanced solid tumor

    Aug11, 2022, Shanghai, China: Maxinovel Pharmaceuticals Co., Ltd. (“Maxinovel” hereafter) announced dosing of first patient with MAX-40279 (multi-tyrosine kinase inhibitor developed by Maxinovel)in combination with KN046 (PD-L1/CTLA-4 bispecific antibody from Alphamab Oncology [stock code: 9966.HK]) in the Phase I/II study (NCT05425602) for solid tumor, at the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

    2022/ 08/ 08
    Maxinovel announces dosing of first patient in Phase I study of MAX-40279 combined with toripalimab in advanced solid tumor

    Maxinovel announces dosing of first patient in Phase I study of MAX-40279 combined with toripalimab in advanced solid tumor

    August 8, 2022, Shanghai, China: Maxinovel Pharmaceuticals Co., Ltd. (“Maxinovel” hereafter) announced dosing of first patient with MAX-40279, a novel multi-tyrosine kinase inhibitor developed by Maxinovel, combined with toripalimab (Anti-PD-1 monoclonal antibody) in the multi-center Phase I study (NCT05369286) for advanced solid tumor at the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

    2022/ 07/ 06
    Maxinovel announces dosing of first patient in Phase II study of MAX-40279 in advanced gastric cancer or gastroesophageal junction cancer

    Maxinovel announces dosing of first patient in Phase II study of MAX-40279 in advanced gastric cancer or gastroesophageal junction cancer

    July 7, 2022, Shanghai, China: Maxinovel Pharmaceuticals Co., Ltd. (“Maxinovel” hereafter) announced dosing of first patient with MAX-40279, a novel multi-tyrosine kinase inhibitor developed by Maxinovel, in the multi-center Phase II study (MAX-40279-006, NCT05395780) of 2nd line or above therapy for advanced gastric cancer or gastroesophageal junction cancer, at the Nanjing Drum Tower Hospital (also named as the Affiliated Hospital of Nanjing University Medical School), Jiangsu, China.

    2022/ 04/ 28
    Maxinovel announces dosing of first patient in Phase II study of MAX-40279 in advanced colorectal cancer

    Maxinovel announces dosing of first patient in Phase II study of MAX-40279 in advanced colorectal cancer

    April 28, 2022, Shanghai, China: Maxinovel Pharmaceuticals Co., Ltd. (“Maxinovel” hereafter) announced dosing of first patient with MAX-40279, a novel multi-tyrosine kinase inhibitor developed by Maxinovel, in the global multi-center Phase II study (MAX-40279-005, NCT05130021) of 3rd line or above therapy for advanced colorectal cancer, at the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

    2022/ 03/ 21
    國家藥品監督管理局批準再極醫藥和君實生物合作的 MAX-40279聯合特瑞普利I期實體瘤臨床試驗

    國家藥品監督管理局批準再極醫藥和君實生物合作的 MAX-40279聯合特瑞普利I期實體瘤臨床試驗

    公司自主研發的MAX-40279(多靶點酪氨酸激酶抑制劑)聯合君實生物特瑞普利單抗(抗PD-1單抗)的一項I期臨床研究(編號:MAX-40279-008)于2022年3月17日獲得國家藥品監督管理局(NMPA)藥品審評中心(CDE)批準。

    2022/ 03/ 10
    Maxinovel Announces Dosing of First Subject in First-in-Human Trial of MAX-40070 Topical Immune Modulator in New Zealand

    Maxinovel Announces Dosing of First Subject in First-in-Human Trial of MAX-40070 Topical Immune Modulator in New Zealand

    March 10, 2022, Shanghai, China: Maxinovel Pharmaceuticals Co., Ltd. (“Maxinovel” hereafter)announces the dosing of the first healthy volunteer in New Zealand with MAX-40070, an investigational topical liniment, in its First-in-human (FIH) clinical trial (MAX-40070-001, NCT05196711).

    More
    ? 男人av在线,377p亚洲欧洲日本大胆色噜噜,国产白丝无码视频在线观看免费,性饥渴的少妇AV无码,日韩乱码人妻无码中文字幕免费,又大又深又爽高潮视频